Inactive Instrument

News Briacell Therapeutics Corp Toronto S.E.

Equities

CA10778Y1043

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Form 8 K	15/06	PU
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	15/06	CI
BriaCell Presents Clinical Efficacy Data at ASCO 2024	03/06	AQ
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024	03/06	CI
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	31/05	AQ
BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	30/05	MT
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer	30/05	AQ
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	30/05	CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05	MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05	MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05	AQ
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05	CI
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024	24/05	AQ
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	21/05	MT
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	18/05	AQ
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15/05	MT
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	15/05	AQ
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	24/04	MT
BriaCell Announces Oral and Poster Presentations at ASCO 2024	24/04	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	10/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Briacell Therapeutics Corp Toronto S.E.

Equities

CA10778Y1043

Summary

Filters